

## **Szakirodalmi hivatkozások:**

- Abhilash, K., et al.: Recognition and management of behavioral disturbances in dementia; In: Primary Care Companion J Clin Psychiatry 2001; 3(3).
- Hébert, R., et al: Factors associated with long-term institutionalization of older people with dementia: data from the Canadian Study of Health and Aging; In: J Gerontol A Biol Sci Med Sci., 2001, 56(11):M693-9.
- Steele, C., et al.: Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease;  
In: Am J Psychiatry. 1990, 147(8): 1049-51.
- Aupperle, P., et al.: Management of aggression, agitation, and psychosis in dementia: Focus on atypical antipsychotics;  
In: Am J Alzheimers Dis Other Demen 2006; 21; 101.
- Arvanitakis, Z., et al.: Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function;  
In: Arch Neurol. 2004;61:661-666.
- Inoue, M., et al.: Diabetes mellitus and the risk of cancer; In: Arch Intern Med. 2006; 166: 1871-1877.
- Osborn, David PJ. et al.: Risk for coronary heart disease in people with severe mental illness; In: British Journal of Psychiatry, 2006, 188, 271-277.
- Regenold, WT., et al.: Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use; In: J Affect Disord. 2002, 70(1): 19-26.
- Toalson, P., et al.: The metabolic syndrome in patients with severe mental illnesses; In: Prim Care Companion J Clin Psychiatrx 2004; 6(4).
- Bushe, C., et al.: Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia;  
In: British Journal of Psychiatry, 2004, 184 (suppl.47), s67-s71.
- Cassidy, F., et al.: Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients;  
In: Am J Psychiatry 1999; 156:1417-1420.
- Cohen, D., et al.: Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders;  
In: Diabetes Care 29:786-791, 2006.
- Thakore, JH., et al.: Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia;  
In: International Journal of Obesity, 2002, 26, 137-141.
- Martina, CM., et al.: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia;  
In: Am J Psychiatry, 2003, 160:284-289.
- Brown, LC., et al.: History of depression increases risk of type 2 diabetes in younger adults;  
In: Diabetes Care, 2005, 28: 1063-1067.
- Everson-Rose, SA., et al.: Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife;  
In: Diabetes Care, 2004, 27:2856-2862.
- Vreeland, B., et al.: A program for managing weight gain associated with atypical antipsychotics;  
In: Psychiatric Services, 2003, 54: 1155-1157.

Lieberman, JA., et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia;  
In: N Engl J Med, 2005; 353:1209-23.

Schneider, LS., et al: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease;  
In: N Engl J Med, 2006; 355:1525-38.

McIntyre RS., et al.: Obesity in bipolar disorder and major depressive disorder: results from a national community survey on mental health and well-being; In: Can J Psychiatry., 2006, 51(5): 274-80.

Roberts, RE., et al.: Prospective association between obesity and depression: evidence from the Alameda County Study;  
In: Int J Obes Relat Metab Disord., 2003, 27(4): 514-21.

Herva, A., et al.: Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study;  
In: Int J Obes (Lond). 2006, 30(3):520-7.

Eaton, WW., et al: Epidemiologic evidence on the comorbidity of depression and diabetes;  
In: J Psychosom Res., 2002, 53(4): 903-6.

Engum, A., et al.: The role of depression and anxiety in onset of diabetes in a large population-based study;  
In: J Psychosom Res., 2007, 62(1): 31-8.

Liebermann, JA., et al.: Metabolic changes associated with antipsychotic use;  
In: Prim Care Companion J Clin Psychiatry 2004;6(supple 2): 8-13.

Jindal, R., et al.: Cardiac risk and schizophrenia; In: J Psychiatry Neurosci, 2005; 30(6):393-5.

Straus, SM., et al.: Antipsychotics and the risk of sudden cardiac death;  
In: Arch Intern Med., 2004, 164(12): 1293-7.

Lawrence, DM., et al.: Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998;  
In: British Journal of Psychiatry, 2003, 182, 31-36.

Glassman, AH., et al.: Schizophrenia, antipsychotic drugs, and cardiovascular disease; In: J Clin Psychiatry., 2005; 66 Suppl 6:5-10.

Schneider, LS., et al.: Risk of death with atypical antipsychotic drug treatment for dementia;  
In: JAMA., 2005;294: 1934-1943.

Prior, P., et al.: Causes of death associated with psychiatric illness; In: J Public Health Med. 1996, 18(4): 381-9.

Osorn David, PJ., et al.: Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's general practice research database; In: Arch Gen Psychiatry. 2007; 64:242-249.

Corell, CU., et al.: Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs; In: J Clin Psychiatry., 2006, 67(4):575-83.

Wooltorton, E., et al.: Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials;  
In: CMAJ, 2002, 167(11): 1269-1270.

Llorente, MD., et al.: Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications;  
In: Clinical Diabetes, 2006, 24(1): 18-24.

Towbin, KE.: Gaining: Pediatric patients and use of atypical antipsychotics; In: Am J Psychiatry, 2006,163:12.

Van Gaal LF.: Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity;  
In: Eur Neuropsychopharmacol., 2006, (Suppl. 3): 142-8.

Newcomer, JW., et al.: Metabolic risk during antipsychotic treatment; In: Clin Ther., 2004, 26(12): 1936-46.

Federovicz, VJ., et al.: Metabolic side effects of atypical antipsychotics in children: a literature review;  
In: J Psychopharmacol., 2005, 19(5):533-50.

Safer, DJ., et al.: A comparison of risperidone-induced weight gain across the age span; In: J Clin Psychopharmacol., 2004, 24(4):429-36.

Hu, G. et al.: Type 2 diabetes and the risk of Parkinson's disease; In: Diabetes Care, 2007, 30:842-847.

Xu, W., et al.: The effect of borderline diabetes on the risk of dementia and Alzheimer's disease; In: Diabetes, 2007, 56:211-216.

Sernyak, MJ., et al.: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia;  
In: Am J Psychiatry, 2002; 159: 561-566.

Gardner, DM., et al.: Modern antipsychotic drugs: a critical overview; CMAJ, 2005; 172(13): 1703-1711.

Wooltorton, E., et al.: Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials; In: CMAJ, 2004, 170(9):1395.

Singh, S., et al.: Increased mortality among elderly patients with dementia using atypical antipsychotics; In: CMAJ, 2005, 173(3):252.

Koro, CE., et al.: An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients; In: Arch Gen Psychiatry., 2002; 59:1021-1026.

Martin, A.: Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data;  
In: Am J Psychiatry, 2004; 161:1125-1127.

Newcomer, JW., et al.: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia;  
In: Arch Gen Psychiatry., 2002; 59: 337-345.

Olfson, M., et al.: Hyperlipidemia following treatment with antipsychotic medications; In: Am J Psychiatry, 2006, 163(10):1821-5.

Guo, JJ., et al.: Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder:  
A retrospective, population-based, case-control study; In: J Clin Psychiatry, 2006, 67(7): 1055-61.

Lambert, BL., et al.: Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia; In: Am J Epidemiol., 2006, 163(7): 672-81.

Guo, JJ., et al.: Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study; In: Pharmacotherapy., 2007; 27(1): 27-35.

Schneider, LS., et al.: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials; In: Am J Geriatr Psychiatry, 2006, 14:191-210.

Ballard, C., et al.: The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease; In: Cochrane Database Syst Rev., 2006, 25;(1).

Wu, RR., et al.: Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia; In: *Psychopharmacology (Berl)*. 2006, 186(4): 572-8.

Olfson, M., et al.: Hyperlipidemia following treatment with antipsychotic medications; In: *Am J Psychiatry* 2006, 163:1821-1825.

Luchsinger, JA., et al.: Relation of diabetes to mild cognitive impairment; *Arch Neurol.*, 2007, 64(4):570-5.

Pevill, P., et al.: Impaired insulin signaling and the pathogenesis of Alzheimer's disease; In: *Drugs Today (Barc)*. 2006, 42(12):785-90.

Steen, E., et al.: Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? In: *J Alzheimers Dis.*, 2005, 7(1):63-80.

Lester-Coll, N., et al.: Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease; In: *J Alzheimers Dis.*, 2006, 9(1): 13-33.

de la Monte, SM. et al.: Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease; In: *J Alzheimers Dis.*, 2005, 7(1):45-61.

Sun, MK. et al.: Links between Alzheimer's disease and diabetes; In: *Drugs Today (Barc)*. 2006, 42(7): 481-9.

Watson, GS., et al.: The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment; In: *CNS Drugs.*, 2003;17(1):27-45.

Haan, MN., et al.: Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease; In: *Nat Clin Pract Neurol*. 2006; 2(3): 159-66.

Craft, S. et al.: Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications; In: *Alzheimer Dis Assoc Disord.*, 2006, 20(4):298-301.

Craft, S. et al.: Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype; In: *Psychoneuroendocrinology.*, 2003, 28(6): 809-22.

Craft, S. et al.: Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment; In: *Curr Alzheimer Res.*, 2007, 4(2): 147-52.

Craft, S. Insulin resistance and cognitive impairment: a view through the prism of epidemiology. *Arch Neurol*. 2005; 62:1043-1044.

Ho, L., et al.: Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease; In: *FASEB J*. 2004; 18(7):902-4.

Rivera EJ., et al.: Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine; In: *J Alzheimers Dis.*, 2005, 8(3): 247-68.

de la Monte, SM., et al.: Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease; In: *J Alzheimers Dis*. 2006, 10(1): 89-109.

Reger, MA., et al.: Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype; In: *Neurobiol Aging.*, 2006, 27(3):451-8.

Craft, S., et al.: Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose;  
In: Arch Gen Psychiatry, 1999; 56: 1135-1140.